uploads///SMG Analysts NTM Recommendations and Targets

Scotts Miracle-Gro: Analysts’ Recommendations in February


Nov. 20 2020, Updated 5:15 p.m. ET

Scotts Miracle-Gro

Scotts Miracle-Gro (SMG) was in the news due to its foray into the cannabis industry. Unlike Canopy Growth (WEED), Aurora Cannabis (ACB), and Aphria (APHA), Scotts Miracle-Gro isn’t directly in the cultivation business (HMMJ). In this part, we’ll discuss analysts’ recommendations for Scotts Miracle-Gro in the next 12 months.

Article continues below advertisement

Analysts’ recommendations

In February, analysts’ consensus recommendation for Scotts Miracle-Gro was a “buy.” The overall recommendation month-over-month from seven analysts remained largely unchanged. Among the seven analysts, one recommended a “strong buy,” three recommended a “buy,” and three recommended a “hold.” None of the analysts recommended a “sell” in February.

Target price

In February, the consensus target price for Scotts Miracle-Gro increased month-over-month to $85.5 from $82.5. On February 21, Scotts Miracle-Gro closed at $80, which implies an upside of ~5.8% if the prices converge over the next 12-month period.

Scotts Miracle-Gro stock has struggled over the past few years. The stock missed the earnings estimate for four of the five recent quarters, which concerned investors. Recently, the company underperformed analysts’ expectations in four of the five earnings releases.

For ongoing updates, visit Market Realist’s Healthcare page.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.